<DOC>
	<DOCNO>NCT00588822</DOCNO>
	<brief_summary>This study do find investigational medication , rituximab , could help relieve symptoms peripheral neuropathy ( numbness [ abnormal protein blood ] weakness low upper extremity ) people monoclonal gammopathy undetermined significance people symptomatic smolder Waldestrom macroglobulinemia . Rituximab antibody attack particular type white blood cell ( B Cell ) . By target B-cells make abnormal protein involve cause nerve trouble , hop damage nerve fiber stop improvement allow proceed .</brief_summary>
	<brief_title>Rituximab Treating Patients With Peripheral Neuropathy Caused Monoclonal Gammopathy Undetermined Significance</brief_title>
	<detailed_description>This Phase II single arm trial evaluate use Rituximab administer standard dose schedule initial cycle therapy , follow re-evaluation 6 month . If progression neuropathy ( indicated increase Neuropathy Impairment Score ( NIS ) great equal 10 modify Rankin Score increase &gt; 1 grade ) patient study . In addition , subject elect pursue active treatment include limited plasmapheresis , high-dose intravenous immuneglobulin ( IVIG ) , chemotherapeutic agent , high dose corticosteroid , condition exclusion criterion develop subsequent enrollment , subject study . If neuropathy stable responding ( NIS &lt; 10 modify Rankin Score increase &lt; 1 grade ) patient would receive Cycle 2 rituximab follow reevaluation 12 month . The study Simon Optimal two-stage Phase II design ( α 5 % , β 10 % , π0 5 % , π1 20 % ) . The minimum clinically important response rate 20 % . The first stage include 21 patient second stage total 41 patient . The treatment would reject few 2 responder first stage few 5 responder second stage . The treatment would accept study least 5 responder 41 patient .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis monoclonal gammopathy undetermined significance ( MGUS ) , evidence 1 follow criterion : Documented monoclonal protein serum ( &lt; 3 g/dL ) urine Monoclonal serum free light chain , least 50 % patient immunoglobulin M ( IgM ) paraprotein ( balance immunoglobulin G ( IgG ) immunoglobulin A ( IgA ) subtypes ) Neuropathy Impairment Score ( NIS ) ≥ 25 Stable progressive neuropathy ( i.e. , currently improve ) , judge NIS value fall ≥ 10 ( enrollment last documented value ) , least 1 month great 3 month prior enrollment No evidence amyloidosis overt lymphoma , overt myeloma , Waldenström macroglobulinemia end organ damage No evidence multiple myeloma , Amyloid Lightchain ( AL ) amyloidosis No evidence Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome , diabetes mellitus , alcohol induce neuropathy , untreated hypothyroidism , vitamin B12 deficiency , Sjögren syndrome , cause neuropathy PATIENT CHARACTERISTICS : Not pregnant Negative serum pregnancy test Fertile patient must use acceptable method birth control treatment 6 month completion treatment One follow birth control measure must use : birth control pill , intrauterine device , contraceptive injection ( DepoProvera ) , barrier method diaphragm , condom contraceptive sponge spermicide Adequate bone marrow function indicate sufficient precursor three cell line cellularity least 20 % bone marrow biopsy within 6 month Platelets &gt; 100,000/mm^3 Absolute neutrophil count ( ANC ) &gt; 1,000/mm^3 Hemoglobin &gt; 7 g/dL Serum creatinine &lt; 3.0 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal No history psychiatric disorder require hospitalization , psychiatric consultation , psychotropic medication within last year Patients control depression eligible , define follow : Stable least 6 month No increase psychotropic medication Exclusion criterion : History HIV infection seropositivity History serological profile suggest prior hepatitis B virus ( HBV ) infection ( i.e. , HbsAg antiHBs antiHBc ) Prior HBV vaccination isolate antiHBs antibody exclusion criterion HBV infection nonvaccinationrelated HBV seropositivity Active infection New York Heart Association class III IV heart disease History baseline ECG trace demonstrate severe recurrent severe recent ( within 3 month ) cardiac dysrhythmia ( e.g. , ventricular tachycardia , torsades de pointes ( `` Twisting Points , '' rapid polymorphic Ventricular Tachycardia ) , serious ventricular dysrhythmias ) require implant defibrillator treatment Confirmed diagnosis systemic lupus erythematosus ( SLE ) An isolated low titer positive antinuclear antibody test without clinical evidence SLE exclusion criterion Concomitant malignancies previous malignancy within last five year , exception adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix Malignancy associate paraneoplastic neuropathy A history severe allergic anaphylactic reaction humanize murine monoclonal antibody A history know severe primary secondary immunodeficiency ( e.g. , common variable immunodeficiency ) Significant uncontrolled medical illness may interfere drug delivery interpretation result PRIOR CONCURRENT THERAPY : No live vaccine therapy within 30 day enrollment No plasmapheresis within 3 month No highdose intravenous immunoglobulin , chemotherapeutic agent , highdose corticosteroid ( &gt; 10 mg daily every day ) within 3 month No systemic corticosteroid within 3 month ( unless need adrenal insufficiency stable dose ≤ 10 mg daily ) No highdose ( &gt; 250 mg/day ) vitamin B6 within past month No prior treatment thalidomide neurotoxic drug ( e.g. , vinca alkaloid , taxol , platinum )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
</DOC>